Urologist recommends daily Viagra to prevent impotence

Sildenafil (Viagra), primarily known for treating erectile dysfunction, is now being proposed for daily use to prevent the onset of impotence. This recommendation comes from Professor Irwin Goldstein, a distinguished urologist at Boston University, who addressed a notable gathering of medical professionals recently.

At a continuing medical education seminar primarily funded by Pfizer, the pharmaceutical company behind Viagra, Professor Goldstein passionately advocated for a daily regimen of sildenafil, stating, "Taking sildenafil nightly can be key to maintaining erectile function in the long run." His assertion was bolstered by anecdotes from numerous men who have embraced this approach, claiming it not only enhances their sexual experiences but also contributes to better overall sexual health.

During a session at New York University, Professor Goldstein shared that he has had “hundreds of men” successfully utilizing Viagra as a preventative measure. He advised, “For those who wish to remain sexually active in five years, consider a quarter of a pill each night. Our observations indicate it promotes and sustains nocturnal erections, which are vital for penile health.”

This statement was made while responding to a query from Dr. Natan Bar-Chama, a urologist at Mount Sinai School of Medicine, who emphasized the necessity of adopting preventive measures in managing sexual health. Dr. Bar-Chama echoed the sentiment of many specialists who advocate for proactive strategies in patient care.

Supporting this viewpoint, a study led by Montorsi et al. (as published in Urology 2000;56:906-11) demonstrated positive outcomes in men with erectile dysfunction, further solidifying the idea that daily use of sildenafil could yield significant long-term benefits. Professor Goldstein called sildenafil a “revolutionary medication” for its role in improving sexual function.

However, the endorsement of daily Viagra use has sparked controversy within the medical community. Renowned sex researchers such as Dr. John Bancroft from Indiana University expressed concern, labeling this approach as “potentially alarming.” Critics like Dr. Leonore Tiefer from New York University have cautioned against the influence of pharmaceutical sponsorship on educational dialogues, calling for more unbiased research.

The recording and dissemination of these discussions could lead to a wider acceptance of the idea of prescribing sildenafil not just for treatment, but as a preventive measure—a transition that could significantly boost Pfizer's market presence.

When queried about possible financial ties to Pfizer, Dr. Bar-Chama acknowledged his occasional speaking engagements for the company but asserted he held no stock. Likewise, Dr. Goldstein mentioned his consulting roles across the pharmaceutical landscape, maintaining that his opinions remain independent and uninfluenced.

Despite the endorsement, Dr. Goldstein noted that sildenafil does come with considerations; it has been reported to exhibit a dropout rate of about 50% in some studies. “I ensure that my statements are backed by evidence. It’s crucial to be transparent about the complexities involved,” he reassured attendees.

The guidelines set by the Accreditation Council for Continuing Medical Education require that any significant financial relationships between speakers and manufacturers be disclosed, but there remain questions about transparency at the New York event.

Dr. Michael Sweeney, who leads Pfizer’s Urology Group, acknowledged Professor Goldstein's enthusiasm but emphasized that the company has yet to observe compelling data endorsing daily sildenafil use.